Concierge
Customer Stories

How past liver-safety failures helped DART‑Met weigh where to start

Sleuth shows founders what has failed in their field and why, so they can choose where to start. Suraj Pavagada was developing a new way to detect liver injury as a Stanford researcher, with no commercial team and investor meetings weeks away. Sleuth’s analysts reviewed ten years of liver-safety setbacks and surfaced a promising opportunity in about a week.

DART-Met

How past liver-safety failures helped DART‑Met weigh where to start

Download the full case study

Partner

DART-Met is a programmable sensing platform designed to reveal biochemical signatures of liver disease and injury that conventional blood tests may miss. Suraj Pavagada, PhD, a Stanford radiology postdoc, is developing it. He came in with two ideas for where to start: catching liver injury earlier in drug trials, or picking patients for MASH trials without a biopsy.

Challenge

He knew the science. What he didn’t know yet was who would buy it first and why, and how to make that case to investors. He asked Sleuth’s analysts to do the market work.

Approach

Outcome

“My father’s liver panels read normal, normal, normal, and then—suddenly, late‑stage cirrhosis. The damage starts long before it shows up on those tests. That gap is the reason DART‑Met exists.”

Suraj Pavagada, PhD

Suraj Pavagada, PhD

Stanford researcher

What ten years of liver setbacks showed

The DART-Met platform detects liver injury, so the question was where it would change a decision, and who would pay. Sleuth’s analysts pulled ten years of liver-safety setbacks, with the FDA actions and trial costs around them. Two lessons cast doubt on the original plan.

Most liver setbacks come late in trials

More than half surfaced at Phase 3 or later, the costliest stretch of development. Catching failures early, the market he’d planned to lead with, is the bigger prize, but proving a test can do it would take years of trial data.

25 liver-safety setbacks by the phase each surfaced, with 13 at Phase 3 or later, on blocks sized by trial cost.
Block width shows trial-cost estimates by phase; Phase 3 takes about two-thirds.

Few were cancer drugs

He’d guessed cancer drugs would be where the most liver safety setbacks were. Only 2 of the 25 setbacks Sleuth analyzed were in oncology. Twenty were small molecules outside cancer. Those developers, not oncology teams, became his targeted buyers later.

The 25 setbacks by disease area, with 2 in oncology and 20 small molecules outside cancer.

Graveyard lessons pointed to a promising place to start

Suraj planned to pitch early detection across drug trials. The analysis showed that would be slow to prove, so Sleuth looked at MASH trial screening, which he's now weighing alongside it.

Two possible starting markets compared on the problem, how to prove the test works, and who pays, then one four-step path from a MASH trial sponsor to early detection.
“Founders need outside input to pressure test their own assumptions. Sleuth’s analysts showed us where liver safety really breaks down in drug development, and it sharpened our commercialization thinking before investor discussions.”

Suraj Pavagada, PhD

Download
Use case

See where programs like yours have failed before you pick a market

Bring your own asset, target, or indication, and Sleuth builds the analysis for you.

More from Sleuth